Pfizer Inc. Loses Lipitor Patent
by RealPTC Expert
Pfizer Inc.’s long dependence on the cholesterol pill Lipitor to produce almost one-fifth of the company’s revenue began eroding from yesterday 30th November, when the drug’s patent protection ended in the U.S. The next step will be rebuilding the world’s biggest drugmaker into a smaller, faster-moving company that focuses on development of biologic drugs and specialty medicines while expanding sales of existing products, such as Lipitor and the erection drug Viagra, in emerging counties such as China, executives said in interviews.
Subscribe to:
Post Comments (Atom)
0 comments:
Leave a Comment